Healthcare / Medical Instruments & SuppliesSaudi
$30.60
-0.08 (-0.26%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 20%
FCF escenarios
weak_data · normalized FCF $1.2M · quality 51.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
37/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$918M
P/E
31.5x
↑EV/EBITDA
14.2x
↑ROE
5.6%
↑Gross Margin
13.9%
↓Debt/Equity
0.38
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+7.1%
FCF CAGR
-78.9%
FCF margin
0.1%
FCF / Net income
0.04x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $876.7M · net income $28.4M · FCF $1.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $876.7M | $876.7M | $877.2M | $776.7M | $713.8M |
| Net Income | $28.4M | $28.4M | $26.2M | $40.1M | $17.6M |
| EBITDA | $76.5M | $76.5M | $93.8M | $112.2M | $66.6M |
| EPS | 0.95 | 0.95 | 0.87 | 1.34 | 0.59 |
| Gross Margin | 13.9% | 13.9% | 15.2% | 16.6% | 21.7% |
| Operating Margin | 4.5% | 4.5% | 6.6% | 9.9% | 5.3% |
| Net Margin | 3.2% | 3.2% | 3.0% | 5.2% | 2.5% |
| Balance Sheet | |||||
| Debt/Equity | 0.38 | 0.38 | 0.41 | 0.71 | 0.44 |
| Cash Flow | |||||
| Free Cash Flow | $1.2M | $1.2M | $281.4M | $-155.5M | $128.9M |
| Returns | |||||
| ROE | 5.6% | 5.6% | 5.1% | 7.8% | 3.7% |
| Valuation | |||||
| P/E | 31.55 | 31.55 | 59.20 | 34.49 | 72.30 |
| EV/EBITDA | 14.24 | 14.24 | 17.75 | 15.39 | 21.36 |
| P/B | 1.80 | 1.80 | 3.03 | 2.70 | 2.70 |
| Growth & Yield | |||||
| Revenue Growth | -0.1% | -0.1% | 12.9% | 8.8% | — |
| EPS Growth | 9.2% | 9.2% | -34.8% | 128.0% | — |
| Dividend Yield | 3.3% | 3.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
41.9%
EPS terminal req.
$2.72
Spread vs growth
-32.7%
5Y implied EPS CAGR
28.2%
EPS terminal req.
$3.29
Spread vs growth
-19.0%
10Y implied EPS CAGR
18.7%
EPS terminal req.
$5.29
Spread vs growth
-9.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-14.6%
Start / end P/E
42.8x → 32.2x
EPS bridge
0.87 → 0.95
Residual
-2.3%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.